View Financial HealthCullinan Therapeutics 配当と自社株買い配当金 基準チェック /06Cullinan Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-0.1%バイバック利回り総株主利回り-0.1%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesConsensus revenue estimates fall by 10% Apr 30Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst Apr 30Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Receive U.S. Food and Drug Administration Acceptance for New Drug Application for Zipalertinib for Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsApr 30Cullinan Therapeutics, Inc., Annual General Meeting, Jun 16, 2026Apr 29Cullinan Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Apr 28We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash WiselyApr 23Consensus revenue estimates decrease by 39% Mar 17President recently sold US$223k worth of stock Feb 24Is Cullinan Therapeutics (NASDAQ:CGEM) In A Good Position To Invest In Growth?Jan 23President recently sold US$99k worth of stock Dec 31Price target increased by 11% to US$28.78 Dec 10Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash MeetingDec 09Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaDec 01Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNov 21Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual MeetingNov 04Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025Oct 27Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025Oct 13Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn SituationOct 10Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung CancerSep 09Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025Aug 07Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth IndexJun 30+ 4 more updatesHere's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn SituationJun 21Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJun 02Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025May 23Price target decreased by 12% to US$28.25 May 12Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United StatesApr 30Cullinan Therapeutics, Inc., Annual General Meeting, Jun 12, 2025Apr 28Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsApr 23Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978Apr 16Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data Apr 08Consensus revenue estimates fall by 52% Mar 07President recently sold US$107k worth of stock Mar 02Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth PlansFeb 27Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior TherapyJan 29New major risk - Shareholder dilution Jan 16Cullinan Therapeutics: Casting A Wide Net With Their Pipeline Jan 08President recently sold US$100k worth of stock Dec 30Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth PlansNov 20Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024Nov 15Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024Nov 05Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusOct 16Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusSep 17Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusSep 16Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024Sep 14Chief Scientific Officer notifies of intention to sell stock Sep 08Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease Aug 30Independent Director exercised options to buy US$402k worth of stock. Jun 13Checking Into Cullinan Therapeutics Jun 09Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of ZipalertinibJun 02Independent Director exercised options to buy US$2.4m worth of stock. May 24Consensus EPS estimates upgraded to US$3.01 loss May 22Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024May 19Cullinan Therapeutics, Inc. Announces Board ChangesMay 17Chief Scientific Officer notifies of intention to sell stock May 08Consensus revenue estimates increase by 19% May 01Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial OfficerApr 30Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In GrowthApr 23Price target increased by 13% to US$28.71 Apr 17Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in fundingApr 16+ 1 more updateCullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024Mar 15Chief Business Officer notifies of intention to sell stock Jan 24New minor risk - Shareholder dilution Jan 19Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesDec 15Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023Nov 04Price target decreased by 11% to US$25.25 Aug 11New minor risk - Profitability Aug 11Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 TrialAug 04Investor sentiment improves as stock rises 17% Jul 17High number of new and inexperienced directors Jul 01Chief Development Officer notifies of intention to sell stock Jun 10Investor sentiment improves as stock rises 16% Jun 06Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid TumorsMay 28Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin LymphomaJan 25Investor sentiment deteriorated over the past week Dec 21Chief Development Officer notifies of intention to sell stock Dec 02Price target decreased to US$34.00 Nov 16Cullinan Oncology Appoints of David P. Ryan to Its Board of DirectorsNov 03Investor sentiment improved over the past week Oct 26Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development Sep 14Cullinan Oncology grants stock options for 125.7K shares Sep 02Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal OfficerAug 16Insider recently sold US$712k worth of stock Aug 06Chief Business Officer notifies of intention to sell stock Jul 22Chief Business Officer notifies of intention to sell stock Jul 15Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth IndexJun 26Insider recently sold US$1.3m worth of stock Jun 25Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).Jun 24Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In GrowthJun 24President recently bought US$100k worth of stock Jun 08Insider recently sold US$4.0m worth of stock May 18Price target decreased to US$39.25 May 17Forecast to breakeven in 2022 May 14Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.May 13Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022May 02決済の安定と成長配当データの取得安定した配当: CGEMの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CGEMの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Cullinan Therapeutics 配当利回り対市場CGEM 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CGEM)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (CGEM) (最長3年)0%注目すべき配当: CGEMは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CGEMは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CGEMの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CGEMが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 10:20終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cullinan Therapeutics, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Julian HarrisonBTIGSamantha Lynn SemenkowCitigroup IncJoshua SchimmerEvercore ISI13 その他のアナリストを表示
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Receive U.S. Food and Drug Administration Acceptance for New Drug Application for Zipalertinib for Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsApr 30
Cullinan Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Apr 28
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash MeetingDec 09
Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid LeukemiaDec 01
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNov 21
Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual MeetingNov 04
Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025Oct 27
Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025Oct 13
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung CancerSep 09
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth IndexJun 30+ 4 more updates
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJun 02
Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025May 23
Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United StatesApr 30
Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsApr 23
Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978Apr 16
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data Apr 08
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior TherapyJan 29
Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024Nov 15
Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024Nov 05
Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusOct 16
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusSep 17
Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusSep 16
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024Sep 14
Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of ZipalertinibJun 02
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in fundingApr 16+ 1 more update
Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024Mar 15
Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesDec 15
Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023Nov 04
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 TrialAug 04
Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid TumorsMay 28
Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin LymphomaJan 25
Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).Jun 24
Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.May 13
